

# 6.1, 6.2, 6.3 Number of PBS prescriptions dispensed for asthma medicines per 100,000 people, 2013–14

Exported from METEOR (AIHW's Metadata Online Registry)

© Australian Institute of Health and Welfare 2024

This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website's material but must attribute the AIHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at <https://creativecommons.org/licenses/by/4.0/>.

Enquiries relating to copyright should be addressed to [info@aihw.gov.au](mailto:info@aihw.gov.au).

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at [meteor@aihw.gov.au](mailto:meteor@aihw.gov.au).

# 6.1, 6.2, 6.3 Number of PBS prescriptions dispensed for asthma medicines per 100,000 people, 2013–14

## Identifying and definitional attributes

<b>Metadata item type:</b>	Indicator
<b>Indicator type:</b>	Indicator
<b>Short name:</b>	Asthma medicines dispensing, 2013-14
<b>METEOR identifier:</b>	611645
<b>Registration status:</b>	<a href="#">Australian Commission on Safety and Quality in Health Care</a> , Standard 23/11/2016 <a href="#">National Health Performance Authority (retired)</a> , Retired 01/07/2016
<b>Description:</b>	Number of prescriptions dispensed for asthma medicines per 100,000 people, age standardised. Data are disaggregated by the area in which the person lives.
<b>Indicator set:</b>	<a href="#">Australian Atlas of Healthcare Variation</a> <a href="#">Australian Commission on Safety and Quality in Health Care</a> , Standard 23/11/2016 <a href="#">National Health Performance Authority (retired)</a> , Retired 01/07/2016

## Collection and usage attributes

<b>Population group age from:</b>	3 to 19 years 20 to 44 years 45 years and over
-----------------------------------	--

### Computation description:

Presented as a number per 100,000 people, age standardised, by Statistical Area Level 3.

Analysis by Statistical Area Level 3 (SA3) is based on postcode of usual residence of the patient which is based on the patient's Medicare enrolment postcode on the date the prescription was dispensed.

SA3s where the total population was less than 2,500 or where the population of interest was less than 200 are excluded.

Suppression protocol for calculating age standardised rates:

Numerator	Total prescriptions dispensed were less than 20 (unrounded data)
Denominator	ERP for one or more five year age groups was less than 30

For the population group 3 to 19 years, the following age groups were used for calculating age standardised rates: 3-9, 10-14, 15-19.

**Computation:** 100,000 x (Numerator ÷ Denominator), age standardised

For more information about age-standardisation, see

</content/index.phtml/itemId/327276>

**Numerator:** Number of PBS prescriptions dispensed for asthma medicines in 2013-14.

### Numerator data elements:

#### Data Element / Data Set

[Pharmaceutical Benefits Scheme \(PBS\) prescription—PBS item prescribed, code NN\[NNN\]A](#)

NMDS / DSS

[Pharmaceutical Benefits Scheme \(PBS\) state/territory data extract 2013-14](#)

Guide for use

Data source type: Administrative by-product data

PBS code	Description
01034K	TERBUTALINE–Injection containing terbutaline sulfate 500 micrograms in 1 mL
01099W	SALBUTAMOL–Capsule containing powder for oral inhalation 200 micrograms (as sulfate) (for use in Ventolin Rotahaler)
01103C	SALBUTAMOL–Oral solution 2 mg (as sulfate) per 5 mL, 150 mL
01252X	TERBUTALINE–Powder for oral inhalation in breath actuated device containing terbutaline sulfate 500 micrograms per dose, 200 doses
01542E	IPRATROPIUM–Nebuliser solution containing ipratropium bromide 250 micrograms (anhydrous) in 1 mL single dose units, 30
02000G	SALBUTAMOL–Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30
02001H	SALBUTAMOL–Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30
02003K	SALBUTAMOL–Nebuliser solution 5 mg (as sulfate) per mL, 30 mL
02065Q	BUDESONIDE–Nebuliser suspension 500 micrograms in 2 mL single dose units, 30
02066R	BUDESONIDE–Nebuliser suspension 1 mg in 2 mL single dose units, 30
02070Y	BUDESONIDE–Powder for oral inhalation in breath actuated device 100 micrograms per dose, 200 doses
02071B	BUDESONIDE–Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses
02072C	BUDESONIDE–Powder for oral inhalation in breath actuated device 400 micrograms per dose, 200 doses
02614N	THEOPHYLLINE–Oral solution 133.3 mg per 25 mL, 500 mL
02634P	THEOPHYLLINE–Tablet 250 mg (sustained release)
02817G	TERBUTALINE–Powder for oral inhalation in breath actuated device containing terbutaline sulfate 500 micrograms per dose, 100 doses
02827T	FLUTICASONE + EFORMOTEROL–Pressurised inhalation containing fluticasone propionate 50 micrograms with eformoterol fumarate dihydrate 5 micrograms per dose, 120 doses
02866W	BUDESONIDE + EFORMOTEROL–Pressurised inhalation containing budesonide 200 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses, 2
02867X	BUDESONIDE + EFORMOTEROL–Pressurised inhalation containing budesonide 50 micrograms with eformoterol fumarate dihydrate 3 micrograms per dose, 120 doses, 2
02878L	CROMOGLYCATE–Capsule containing powder for oral inhalation containing sodium cromoglycate 20 mg (for use in Intal Spinhaler or Intal Halermatic)
02938P	BUDESONIDE + EFORMOTEROL–Pressurised inhalation containing budesonide 100 micrograms with eformoterol fumarate dihydrate 3 micrograms per dose, 120 doses, 2

03491R	TERBUTALINE–Injection containing terbutaline sulfate 500 micrograms in 1 mL
03495Y	SALBUTAMOL–Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation)
03496B	SALBUTAMOL–Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30
03497C	SALBUTAMOL–Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30
05134F	INDACATEROL–Capsule containing powder for oral inhalation 150 micrograms (as maleate) (for use in Breezhaler)
05137J	INDACATEROL–Capsule containing powder for oral inhalation 300 micrograms (as maleate) (for use in Breezhaler)
08136F	EFORMOTEROL–Capsule containing powder for oral inhalation containing eformoterol fumarate dihydrate 12 micrograms (for use in Foradile Aerolizer)
08141L	SALMETEROL–Powder for oral inhalation in breath actuated device 50 micrograms (as xinafoate) per dose, 60 doses
08147T	FLUTICASONE–Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms per dose, 60 doses
08148W	FLUTICASONE–Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms per dose, 60 doses
08149X	FLUTICASONE–Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms per dose, 60 doses
08230E	THEOPHYLLINE–Tablet 200 mg (sustained release)
08231F	THEOPHYLLINE–Tablet 300 mg (sustained release)
08238N	IPRATROPIUM–Nebuliser solution containing ipratropium bromide 500 micrograms (anhydrous) in 1 mL single dose units, 30
08239P	EFORMOTEROL–Powder for oral inhalation in breath actuated device containing eformoterol fumarate dihydrate 6 micrograms per dose, 60 doses
08240Q	EFORMOTEROL–Powder for oral inhalation in breath actuated device containing eformoterol fumarate dihydrate 12 micrograms per dose, 60 doses
08288F	SALBUTAMOL–Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation)
08334P	CROMOGLYCATE–Pressurised inhalation containing sodium cromoglycate 5 mg per dose, 112 doses (CFC-free formulation)
08345F	FLUTICASONE–Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC-free formulation)
08346G	FLUTICASONE–Pressurised inhalation containing fluticasone propionate 250 micrograms per dose, 120 doses (CFC-free formulation)
08354Q	SALBUTAMOL–Pressurised inhalation in breath actuated device 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation)
08365G	NEDOCROMIL–Pressurised inhalation containing nedocromil sodium 2 mg per dose, 112 doses (CFC-free formulation)

08406K	BECLOMETHASONE–Pressurised inhalation containing beclomethasone dipropionate 50 micrograms per dose, 200 doses (CFC-free formulation)
08407L	BECLOMETHASONE–Pressurised inhalation containing beclomethasone dipropionate 100 micrograms per dose, 200 doses (CFC-free formulation)
08408M	BECLOMETHASONE–Pressurised inhalation in breath actuated device containing beclomethasone dipropionate 50 micrograms per dose, 200 doses (CFC-free formulation)
08409N	BECLOMETHASONE–Pressurised inhalation in breath actuated device containing beclomethasone dipropionate 100 micrograms per dose, 200 doses (CFC-free formulation)
08430Q	FLUTICASONE + SALMETEROL–Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses
08431R	FLUTICASONE + SALMETEROL–Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses
08432T	FLUTICASONE + SALMETEROL–Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses
08516F	FLUTICASONE–Pressurised inhalation containing fluticasone propionate 50 micrograms per dose, 120 doses (CFC-free formulation)
08517G	FLUTICASONE + SALMETEROL–Pressurised inhalation containing fluticasone propionate 50 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation)
08518H	FLUTICASONE + SALMETEROL–Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation)
08519J	FLUTICASONE + SALMETEROL–Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation)
08625Y	BUDESONIDE + EFORMOTEROL–Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses
08627C	MONTELUKAST–Tablet, chewable, 4 mg (as sodium)
08628D	MONTELUKAST–Tablet, chewable, 5 mg (as sodium)
08671J	IPRATROPIUM–Pressurised inhalation containing ipratropium bromide 21 micrograms per dose, 200 doses (CFC-free formulation)
08750M	BUDESONIDE + EFORMOTEROL–Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with eformoterol fumarate dihydrate 12 micrograms per dose, 60 doses, 2
08767K	CROMOGLYCATE–Pressurised inhalation containing sodium cromoglycate 1 mg per dose, 200 doses (CFC-free formulation)
08796Y	BUDESONIDE + EFORMOTEROL–Powder for oral inhalation in breath actuated device containing budesonide 100 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses

08853Y	CICLESONIDE—Pressurised inhalation 80 micrograms per dose, 120 doses (CFC-free formulation)
08854B	CICLESONIDE—Pressurised inhalation 160 micrograms per dose, 120 doses (CFC-free formulation)
09745X	OMALIZUMAB—Powder for injection 150 mg with diluent
09746Y	OMALIZUMAB—Powder for injection 150 mg with diluent
10007Q	FLUTICASONE + EFORMOTEROL—Pressurised inhalation containing fluticasone propionate 125 micrograms with eformoterol fumarate dihydrate 5 micrograms per dose, 120 doses
10008R	FLUTICASONE + EFORMOTEROL—Pressurised inhalation containing fluticasone propionate 250 micrograms with eformoterol fumarate dihydrate 10 micrograms per dose, 120 doses
10015D	BUDESONIDE + EFORMOTEROL—Pressurised inhalation containing budesonide 100 micrograms with eformoterol fumarate dihydrate 3 micrograms per dose, 120 doses
10018G	BUDESONIDE + EFORMOTEROL—Pressurised inhalation containing budesonide 200 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses
10024N	BUDESONIDE + EFORMOTEROL—Pressurised inhalation containing budesonide 50 micrograms with eformoterol fumarate dihydrate 3 micrograms per dose, 120 doses
10059K	GLYCOPYRRONIUM—Capsule containing powder for oral inhalation 50 micrograms (as bromide) (for use in Breezhaler)

**Denominator:**

**Denominator data elements:**

Total population of age group

**Data Element / Data Set**

[Person—estimated resident population of Australia, total people N\[N\(7\)\]](#)

**Data Source**

[ABS Estimated resident population \(total population\)](#)

**Guide for use**

ABS Estimated resident population as at June 2001

Data source type: Census based plus administrative by-product data

**Disaggregation:**

Statistical Area Level 3, which have been derived from [Postcode—Australian \(person\)](#):

- Statistical Area Level 3 (SA3s) are geographic areas defined in the ABS Australian Statistical Geography Standard (ASGS). The aim of SA3s is to create a standard framework for the analysis of ABS data at the regional level through clustering groups of SA2s that have similar regional characteristics. There are 333 spatial SA3s covering the whole of Australia without gaps or overlaps. They are designed to provide a regional breakdown of Australia. SA3s generally have a population of between 30,000 and 130,000 people. There are approximately 50 with fewer than 30,000 people and 35 with more than 130,000 as at 30 June 2011. For further information see the ABS publication, Australian Statistical Geography Standard (ASGS): Volume 1 – Main Structure and Greater Capital City Statistical Areas, July 2011 (cat. no. 1270.0.55.001).

## Disaggregation data elements:

### Data Element / Data Set

[Person—age, total years N\[NN\]](#)

NMDS / DSS

[COMPLETE - Pharmaceutical Benefits Scheme \(PBS\) Pharmacy claim script detail](#)

#### Guide for use

Age of the person is based on the patient's Medicare enrolment date of birth and the date the prescription was dispensed.

Data is disaggregated by the following age groups:

- 3 to 19 years
- 20 to 44 years
- 45 and over.

### Data Element / Data Set

[Address—Australian postcode, Australian postcode code \(Postcode datafile\) {NNNN}](#)

NMDS / DSS

[COMPLETE - Pharmaceutical Benefits Scheme \(PBS\) Pharmacy claim script detail](#)

#### Guide for use

Postcode is based on the patient's Medicare enrolment postcode on the date the prescription was dispensed.

GPO postcodes 2001, 2124, 3001, 4001, 5001, 6843 excluded from the SA3 analysis but included in state/territory and national level analysis.

Data source type: Administrative by-product data

Used for disaggregation by Statistical Area Level 3.

### Data Element / Data Set

[Address—statistical area, level 3 \(SA3\) code \(ASGS 2011\) NNNNN](#)

## Representational attributes

<b>Representation class:</b>	Rate
<b>Data type:</b>	Integer
<b>Unit of measure:</b>	Service event
<b>Format:</b>	NN[NNNN]

## Data source attributes

**Data sources:****Data Source**

[ABS Estimated resident population \(total population\)](#)

**Frequency**

Quarterly

**Data quality statement**

[ABS Estimated resident population \(total population\), QS](#)

**Data custodian**

Australian Bureau of Statistics

## Accountability attributes

**Reporting requirements:** Australian Commission of Safety and Quality in Health Care's Atlas of Healthcare Variation, released November 2015

**Organisation responsible for providing data:** Department of Health

**Accountability:** Australian Commission of Safety and Quality in Health Care

## Source and reference attributes

**Submitting organisation:** National Health Performance Authority